{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:48:14Z","timestamp":1772552894730,"version":"3.50.1"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The treatment efficiency and predictors of atezolizumab plus bevacizumab therapy for unresectable hepatocellular carcinoma in real-world practice have not been established. This study aimed to assess the efficacy and safety of atezolizumab plus bevacizumab and to investigate predictors of progression-free survival and overall survival. Patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy in 19 hospitals were enrolled before treatment and observed prospectively. The outcomes of 222 patients in this cohort were analyzed. The objective response rate and disease control rate were 22.0% and 70.6%, respectively, whereas the median progression-free survival was 5.7 months. Independent risk factors for shortened progression-free survival were younger age (&lt;75 years; 3.9 months vs. 8.6 months), higher number of intrahepatic tumors (\u22655; 4.0 months vs. 7.9 months), macrovascular invasion (2.3 months vs. 6.7 months), and higher neutrophil-to-lymphocyte ratio (\u22653.03; 3.0 months vs. 7.8 months). The median overall survival was not reached; however, independent risk factors for shortened overall survival were absence of hyperlipidemia, higher number of intrahepatic tumors (\u22655), macrovascular invasion, higher \u03b1-fetoprotein level (\u2265400 ng\/mL), worse Child\u2013Pugh score (\u22656), and higher neutrophil-to-lymphocyte ratio (\u22653.03). Severe adverse events (grade \u22653) were observed in 96 patients (36.0%), with proteinuria being the most frequent. In conclusion, patients with older age, lower number of intrahepatic tumors, absent macrovascular invasion, and lower neutrophil-to-lymphocyte ratio are expected to have better progression-free survival with atezolizumab plus bevacizumab therapy for unresectable hepatocellular carcinoma.<\/jats:p>","DOI":"10.1371\/journal.pone.0294590","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T19:19:23Z","timestamp":1704223163000},"page":"e0294590","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study"],"prefix":"10.1371","volume":"19","author":[{"given":"Machiko","family":"Kai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Hikita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maesaka","family":"Kazuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Tahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Shinkai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Ohkawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutoshi","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Yakushijin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-607X","authenticated-orcid":true,"given":"Ryotaro","family":"Sakamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadaharu","family":"Iio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatoshi","family":"Nawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruyasu","family":"Kakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Usui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuho","family":"Imanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsugiko","family":"Oze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohide","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5036-3457","authenticated-orcid":true,"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"issue":"20","key":"pone.0294590.ref001","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"RS Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0294590.ref002","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1111\/liv.15405","article-title":"Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma","volume":"42","author":"M Vithayathil","year":"2022","journal-title":"Liver Int"},{"issue":"3","key":"pone.0294590.ref003","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000514174","article-title":"Management of hepatocellular carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update","volume":"10","author":"M Kudo","year":"2021","journal-title":"Liver Cancer"},{"issue":"Suppl 1","key":"pone.0294590.ref004","first-page":"73158","article-title":"Trial design and endpoints in hepatocellular carcinoma: AASLD Consensus Conference","author":"JM Llovet","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"pone.0294590.ref005","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jhep.2021.07.004","article-title":"Systemic treatment of hepatocellular carcinoma: An EASL position paper","volume":"75","author":"J Bruix","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"pone.0294590.ref006","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s10637-021-01185-4","article-title":"Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice","volume":"40","author":"Y Hayakawa","year":"2022","journal-title":"Invest New Drugs"},{"issue":"5","key":"pone.0294590.ref007","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.3390\/curroncol28050352","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a predictive marker of response to atezolizumab plus bevacizumab for hepatocellular carcinoma","volume":"28","author":"Y Eso","year":"2021","journal-title":"Curr Oncol"},{"issue":"9","key":"pone.0294590.ref008","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/hepr.13797","article-title":"Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice","volume":"52","author":"T Tanaka","year":"2022","journal-title":"Hepatol Res"},{"issue":"3","key":"pone.0294590.ref009","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1002\/cam4.5161","article-title":"Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment","volume":"12","author":"YE Chon","year":"2023","journal-title":"Cancer Med"},{"issue":"5","key":"pone.0294590.ref010","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1007\/s12072-022-10358-z","article-title":"Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study","volume":"16","author":"T Hatanaka","year":"2022","journal-title":"Hepatol Int"},{"issue":"4","key":"pone.0294590.ref011","first-page":"1899","article-title":"Combination of CRAFITY score with alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma","volume":"12","author":"W Teng","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"7","key":"pone.0294590.ref012","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00535-021-01788-x","article-title":"Evidence-based clinical practice guidelines for Liver Cirrhosis 2020","volume":"56","author":"H Yoshiji","year":"2021","journal-title":"J Gastroenterol"},{"issue":"7","key":"pone.0294590.ref013","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/hepr.13678","article-title":"Evidence-based clinical practice guidelines for liver cirrhosis 2020","volume":"51","author":"H Yoshiji","year":"2021","journal-title":"Hepatol Res"},{"issue":"6","key":"pone.0294590.ref014","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"PJ Johnson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0294590.ref015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000479984","article-title":"Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function","volume":"6","author":"A Hiraoka","year":"2017","journal-title":"Liver Cancer"},{"issue":"2","key":"pone.0294590.ref016","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"EA Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"pone.0294590.ref017","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"R Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"1","key":"pone.0294590.ref018","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"WJ Youden","year":"1950","journal-title":"Cancer"},{"issue":"3","key":"pone.0294590.ref019","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/hepr.13741","article-title":"Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy","volume":"52","author":"K Maesaka","year":"2022","journal-title":"Hepatol Res"},{"issue":"11","key":"pone.0294590.ref020","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.3390\/cancers12113078","article-title":"Hypothyroidism is a predictive factor for better clinical outcomes in patients with advanced hepatocellular carcinoma undergoing lenvatinib therapy","volume":"12","author":"M Shomura","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"pone.0294590.ref021","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1159\/000509387","article-title":"Analysis of post-progression survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib","volume":"98","author":"Y Ando","year":"2020","journal-title":"Oncology"},{"issue":"7","key":"pone.0294590.ref022","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.3390\/curroncol29070381","article-title":"Pretreatment modified albumin-bilirubin grade is an important predictive factor associated with the therapeutic response and the continuation of atezolizumab plus bevacizumab combination therapy for patients with unresectable hepatocellular carcinoma","volume":"29","author":"T Tanaka","year":"2022","journal-title":"Curr Oncol"},{"issue":"2","key":"pone.0294590.ref023","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3390\/cancers14020343","article-title":"The prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab","volume":"14","author":"JH Wang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"pone.0294590.ref024","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/hepr.13732","article-title":"Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis","volume":"52","author":"M Chuma","year":"2022","journal-title":"Hepatol Res"},{"issue":"7","key":"pone.0294590.ref025","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.3390\/cancers14071747","article-title":"Atezolizumab\/bevacizumab vs. lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a real-world, multi-center study","volume":"14","author":"BK Kim","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"pone.0294590.ref026","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/liv.15102","article-title":"Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma","volume":"42","author":"J Cheon","year":"2022","journal-title":"Liver Int"},{"issue":"4","key":"pone.0294590.ref027","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/cncr.34559","article-title":"Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice","volume":"129","author":"M Nakagawa","year":"2023","journal-title":"Cancer"},{"issue":"7","key":"pone.0294590.ref028","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/hepr.13771","article-title":"Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma","volume":"52","author":"K Maesaka","year":"2022","journal-title":"Hepatol Res"},{"issue":"20","key":"pone.0294590.ref029","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/cam4.4763","article-title":"Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis","volume":"11","author":"T Tada","year":"2022","journal-title":"Cancer Med"},{"issue":"9","key":"pone.0294590.ref030","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/bjc.2017.70","article-title":"Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy","volume":"116","author":"A Nosrati","year":"2017","journal-title":"Br J Cancer"},{"issue":"21","key":"pone.0294590.ref031","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","article-title":"Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations","volume":"24","author":"CH Kugel","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"8","key":"pone.0294590.ref032","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"AX Zhu","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"pone.0294590.ref033","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/10781552221077039","article-title":"Poor tolerability of lenvatinib in elderly patients \u226580 years old with hepatocellular carcinoma: A multicenter observational study","volume":"29","author":"A Kinoshita","year":"2023","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"pone.0294590.ref034","first-page":"474","article-title":"Neutrophil-to-lymphocyte ratio, past, present and future perspectives","volume":"122","author":"R. Zahorec","year":"2021","journal-title":"Bratisl Lek Listy"},{"issue":"11","key":"pone.0294590.ref035","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12032-014-0264-5","article-title":"Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib","volume":"31","author":"LG da Fonseca","year":"2014","journal-title":"Med Oncol"},{"issue":"9","key":"pone.0294590.ref036","doi-asserted-by":"crossref","first-page":"14408","DOI":"10.18632\/oncotarget.14797","article-title":"Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197\u2013215 second-line study for advanced hepatocellular carcinoma","volume":"8","author":"N Personeni","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"pone.0294590.ref037","doi-asserted-by":"crossref","first-page":"376","DOI":"10.15537\/smj.2020.4.24911","article-title":"A combination of the preoperative neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as a useful predictor of survival outcomes following the transarterial chemoembolization of huge hepatocellular carcinoma","volume":"41","author":"J Liu","year":"2020","journal-title":"Saudi Med J"},{"issue":"6","key":"pone.0294590.ref038","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/MEG.0000000000002356","article-title":"Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis","volume":"34","author":"T Tada","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"14","key":"pone.0294590.ref039","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1002\/cam4.3135","article-title":"Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy","volume":"9","author":"S Dharmapuri","year":"2020","journal-title":"Cancer Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T19:19:54Z","timestamp":1704223194000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294590"}},"subtitle":[],"editor":[{"given":"Satoru","family":"Hagiwara","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0294590","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]}}}